Company intelligence / Profile preview
Third Harmonic Bio
San Francisco, California, USAthirdharmonicbio.com ↗
- Ownership
- Public · THRD
- Development stage
- Phase 1
01
Overview
The company has completed Phase 1 single and multiple ascending dose trials for THB335 in healthy volunteers, demonstrating dose-dependent reductions in serum tryptase (a biomarker of mast cell activation). However, the company has announced plans for liquidation and dissolution in April 2025, with stockholder approval to be sought on June 5, 2025.
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyImmunology
- Modalities
- Small moleculesoral KIT inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Third Harmonic Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Third Harmonic Bio.